In a bold move, Vaccinex has forged eight new antibody discovery agreements with leading pharmaceutical and biotechnology companies, as well as strategic partners specializing in antibody services. These partnerships strategically integrate Vaccinex’s ActivMAb technology, renowned for its ability to tackle complex multi-pass membrane targets previously deemed difficult to drug.

Over the past three months, Vaccinex has inked deals with three major players in the pharmaceutical and biotech sectors, along with five key strategic partners boasting expertise in transgenic animal species and vast synthetic antibody libraries. This collaborative effort aims to capitalize on ActivMAb’s cutting-edge “Antigen Virus” application, a breakthrough approach facilitating the discovery of antibodies against intricate protein targets like ion channels and G-protein coupled receptors (GPCRs), pivotal in cancer therapy and antibody drug conjugates (ADC) development.

Dr. Maurice Zauderer, President and CEO of Vaccinex, expressed enthusiasm about the recent developments, stating, “We have recently achieved significant milestones in selecting high-value antibodies against challenging multi-pass membrane targets. This surge of interest in our technology underscores its unique capabilities and potential to address unmet medical needs. We believe these partnerships reflect a resurgence of optimism in the biotech sector, driving attention towards innovative pipelines neglected during recent downturns. Through ongoing collaborations, we aim to harness the full potential of ActivMAb Antibody Discovery solutions to expedite the development of novel therapeutics with substantial clinical impact.”

Vaccinex remains committed to revolutionizing treatment paradigms for Alzheimer’s disease and cancer through pioneering research and strategic partnerships, firmly positioning itself as a frontrunner in the biotechnology landscape.